View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 18, 2022

Avrobio reports positive data from Phase I/II cystinosis gene therapy trial

The trial is assessing the safety and efficacy of AVR-RD-04 in adults with the infantile form of cystinosis.

Avrobio has reported positive interim findings from a Phase I/II clinical trial of investigational gene therapy, AVR-RD-04, for cystinosis.

AVR-RD-04 is claimed to genetically modify the hematopoietic stem cells (HSC) of the patient to express a functional version of cystinosin.

Cystinosin is a protein that is deficient in cystinosis patients. 

The collaborator-sponsored trial underway is assessing the safety and efficacy of AVR-RD-04 in adults with the infantile form of cystinosis.

These subjects have received prior treatment with cysteamine, the existing standard of care (SOC). 

According to the initial findings, two subjects had stabilisation of the Beery – Buktenica Developmental Test of the visual-motor integration (VMI) scores and enhanced motor coordination and visual perception following treatment with the gene therapy.

This standardised test is used to assess the brain’s ability to understand and translate visual data into an exact motor response.

Furthermore, post-treatment, subjects were found to be able to produce and distribute functional cystinosin protein across the body, averting the pathological build-up of cystine crystals​.

Continued engraftment was reported with stable vector copy number (VCN) in patients after 12 months.

A favourable safety profile was observed in the trial without any adverse events linked to the drug product reported so far.

Avrobio chief medical officer Essra Ridha said: “We believe the interim data from this ongoing clinical trial demonstrate the potential of gene therapy using patient’s own hematopoietic stem cells to impact the body head-to-toe by restoring functional cystinosin and reducing the accumulation of cystine crystals systemically. 

“With proof-of-concept demonstrated, we continue to lay the groundwork for an Avrobio-sponsored clinical trial planned to begin in 2023 and look forward to our interactions with regulators on our clinical and Chem­istry Man­u­fac­tur­ing and Con­trols (CMC) strategy later this year.”

In February last year, the company reported a complete clearance of toxic substrate in the kidney biopsy of a subject dosed with its plato gene therapy platform in the Phase II FAB-GT trial of AVR-RD-01 for Fabry disease.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena